News | May 11, 2026
Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies
The Committee backed the combination based on results from the CAPItello-281 Phase III trial, marking a key milestone in the regulatory pathway for AstraZeneca’s targeted therapy strategy in prostate cancer
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
While Drugs for Neglected Diseases initiative (DNDi) drives the R&D for neglected diseases, we collaborate with pharmaceutical companies at multiple stages, including sourcing promising molecules
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The approval was driven by data from the Phase III TULIP-SC trial
Subscribe To Our Newsletter & Stay Updated
